Fig. 7: KCTD9 inhibits CRC growth and metastasis in vivo.
From: KCTD9 inhibits the Wnt/β-catenin pathway by decreasing the level of β-catenin in colorectal cancer
A, B SW620 cells without (pCDH) or with overexpression KCTD9 (pCDH-KCTD9) were subcutaneously inoculated into nude mice. Images (A) and weights (B) of the excised xenografts recovered at 21 days. Data represent mean ± SD, n = 6 mice per group, two-tailed Student’s t test, ***p < 0.001. C–E SW620 cells without (pCDH) or with overexpression KCTD9 (pCDH-KCTD9) were inoculated under the spleen capsule of nude mice to measure spleen to liver metastasis using a luciferase-based bioluminescence assay. Images of the excised spleens recovered at 28 days (C) along with bioluminescence images of whole livers (D) and hematoxylin and eosin (E) stained sections of liver tissue. n = 5 mice per group. F, G Tissue microarrays containing 80 human CRC tissues were analyzed in parallel for expression of KCTD9 and β-catenin using immunohistochemical (IHC) staining. Representative staining of cases with low and high expression of KCTD9, respectively (F) and quantification of IHC staining as immunoreactive scores (IRS) (G). The Pearson correlation coefficient (r) was calculated as shown. (n = 80).
